Day One Biopharmaceuticals 2023 Investor Presentation | Cancer Drug Development

Day One Biopharmaceuticals presented its targeted cancer therapy portfolio in August 2023, focusing on tovorafenib (DAY101), an investigational oral RAF inhibitor being developed for pediatric low-grade glioma and other genomically-defined cancers. The company outlined its mission to develop medicines for children with cancer while expanding to adolescent and adult populations, with projected cash runway into 2026.